ArticleApplied and environmental microbiology2025
Photoinactivation of influenza viruses by modulated indoor daylight spectrum and intensity.
Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Influenza claims over 290,000 lives annually, and the annual flu season remains a major public health challenge. Within the domain of health-focused architectural design, indoor daylight emerges as a potential shield against microbial threats. Yet, a significant gap in our understanding remains: the effect of indoor daylight on viruses. To bridge this knowledge gap, we used a living lab setup to investigate the impact of modulated indoor daylight on the stability of genomic material and persistence of infectivity of enveloped influenza A and B viruses, along with the non-enveloped bacteriophage MS2 on an environmental surface of glass. Indoor daylight modulation showed capacity for viral inactivation with differential activity depending on spectrum, intensity, and duration of exposure. Intensity was the most impactful, significantly reducing the infectivity of influenza A virus and both the infectivity and amount of recoverable genomic material of influenza B virus following 8 h of exposure. Even at low-intensity light, comparable to light passing through traditional blinds, spectrum-modulated, blue-enriched light significantly reduced the infectivity of influenza A and B within 8 h. Moreover, for all viruses, the infectivity declined before the stability of genomic material, suggesting a mechanism of photoinactivation via the disruption of viral proteins involved in infection. This research emphasizes the paramount importance of considering daylighting conditions as a strategic approach to control infectious disease transmission in built environments. Our findings not only underscore this significance but also offer innovative pathways to transform indoor spaces into safer, healthier environments for everyone.IMPORTANCEThis study examined the interplay between indoor daylighting and viruses, specifically influenza A, influenza B, and MS2 bacteriophage in a simulated indoor environment on a surface material of glass. It demonstrated that indoor daylight modulation was able to inactivate influenza A and B following 8 h of exposure at high-intensity and low-intensity blue-enriched light; however, the stability of genomic material of influenza A was unaffected until at least 24 h of exposure. These results, which focus on differences between stability of genomic material and infectivity, provide deeper insight into viral photoinactivation mechanisms, and the use of a living-lab setup lays the foundation for a framework for healthy building design using indoor daylight modulation for infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.